Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
Tony Hagen, Senior Editor, The Center for Biosimilars
Advertisement
Articles by Tony Hagen, Senior Editor, The Center for Biosimilars
Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months
CROs are also adapting to pandemic.
Advertisement
Latest Updated Articles
AMCP Nexus 2021: Jen Norton, VP & Head of U.S. Value & Access at Amgen Talks Biosimilar Trends and What to Expect in the Next YearPublished: October 19th 2021 | Updated:
FDA Issues Contingency Guidance for Clinical Trials Affected by COVID-19Published: March 19th 2020 | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025
2
Cigna Announces ‘Rebate-Free’ Pharmacy Benefit Model Starting in 2027
3
Rebates Play a Major Role in Whether Health Plans Restrict Access to Specialty Drugs | AMCP Nexus 2025
4
Paul Ryan Proposes Risk Pools and Medicare Overhaul to Reform Healthcare | AMCP Nexus 2025
5
